logo
Botulism contamination risk led to US-wide recall of canned tuna

Botulism contamination risk led to US-wide recall of canned tuna

Express Tribune12-02-2025

Listen to article
Several canned tuna products sold by major US grocers, including Costco, Trader Joe's, and Walmart, have been recalled due to concerns over possible botulism contamination, the US Food and Drug Administration (FDA) announced Monday.
The recall affects Genova, Van Camp's, H-E-B, and Trader Joe's branded tuna, distributed across multiple states and Washington, DC Tri-Union Seafoods, a subsidiary of Thai Union, initiated the recall after a supplier identified a manufacturing defect in the cans' 'easy open' pull lids, which could compromise the seal and lead to contamination.
Botulism risk from defective seals
Tri-Union Seafoods warned that the defective lids could cause cans to leak or become contaminated with Clostridium botulinum, the bacteria responsible for botulism—a rare but potentially fatal illness.
'The defect may compromise the integrity of the seal, especially over time, causing it to leak, or worse, be contaminated with clostridium botulinum, a potentially fatal form of food poisoning,' the company said in the FDA's recall notice.
Consumers have been urged to immediately stop consuming the recalled tuna, even if it appears normal and does not smell spoiled, as botulism can develop without visible signs of contamination.
FDA and CDC warn of severe health risks
The US Centers for Disease Control and Prevention (CDC) classifies botulism as a serious medical emergency that can cause:
Muscle paralysis
Difficulty breathing
Death if untreated
The bacteria thrive in low-oxygen environments, such as improperly sealed canned foods. Even a small exposure to the toxin can result in life-threatening complications if not treated promptly.
Widespread Retail Impact Across US
The recalled tuna was distributed to major grocery stores across multiple states:
Trader Joe's: Sold in Delaware, Illinois, Indiana, Iowa, Kansas, Kentucky, Maryland, Michigan, Minnesota, Missouri, Nebraska, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Virginia, Washington D.C., and Wisconsin.
Costco (Genova brand): Florida, Georgia
H-E-B (Texas)
Harris Teeter, Publix, H-E-B, Kroger, Safeway, Walmart (Genova 5-ounce brand): Alabama, Arizona, Arkansas, California, Florida, Georgia, North Carolina, New Jersey, Tennessee, Texas
Van Camp's at Walmart and independent retailers: Florida, New Jersey, Pennsylvania
Walmart stores: Alabama, Arizona, Arkansas, California, Florida, Georgia, Louisiana, Mississippi, Nevada, New Mexico, North Carolina, Oklahoma, Oregon, South Carolina, Tennessee, Texas, and Washington
What Consumers Should Do
Consumers who have purchased recalled tuna are advised to:
Return the product to the retailer for a full refund.
Dispose of it immediately to prevent accidental consumption.
Contact Tri-Union Seafoods at support@thaiunionhelp.zendesk.com or 833-374-0171 (Monday-Friday, 9:00 AM - 5:00 PM EST) to request a retrieval kit and replacement product coupon.
No Reported Illnesses So Far
As of Monday, no illnesses linked to the recalled tuna have been reported, according to the FDA and Tri-Union Seafoods. However, consumers experiencing symptoms of botulism poisoning are urged to seek immediate medical attention.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sanofi's $9.5B acquisition of Blueprint Medicines strengthens rare immunology portfolio
Sanofi's $9.5B acquisition of Blueprint Medicines strengthens rare immunology portfolio

Express Tribune

time02-06-2025

  • Express Tribune

Sanofi's $9.5B acquisition of Blueprint Medicines strengthens rare immunology portfolio

In a major move underscoring its ambition to lead in rare diseases and immunology, French pharmaceutical giant Sanofi announced its plan to acquire US-based Blueprint Medicines for up to $9.5 billion. The deal was announced by a press release on Sanofi's website. It is the largest by a European healthcare company this year and will see Sanofi paying $129 per share in cash, a significant premium that sent Blueprint's stock soaring in premarket trading. Blueprint Medicines, known for its specialty in treating systemic mastocytosis a rare blood disorder marked by the overproduction of mast cells brings to Sanofi a strong foothold in a niche yet critical area of medicine. The acquisition adds the FDA-approved drug Ayvakit, the only treatment for advanced systemic mastocytosis, to Sanofi's growing immunology portfolio. Sanofi CEO Paul Hudson framed the deal as a strategic leap forward, enhancing the company's pipeline and reinforcing its transformation into a global leader in immunology. We announced an agreement to acquire Blueprint Medicines, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases. — Sanofi (@sanofi) June 2, 2025 With a promising pipeline including next-generation therapies like elenestinib and BLU-808, the acquisition fits into Sanofi's broader ambition of innovation despite recent setbacks, including a failed lung disease drug trial. Industry analysts from JP Morgan praised the acquisition for its strategic and financial merits, forecasting Ayvakit could generate $2 billion in annual sales by 2030. Sanofi's ongoing spree of acquisitions, including Vigil Neuroscience and Inhibrx, signals a company doubling down on R&D investments to reshape its future. The acquisition aligns with Sanofi's broader strategy to invest heavily in US manufacturing and research, tapping into incentives and momentum driven by recent government policies. With Blueprint Medicines now joining its portfolio, Sanofi cements its stake in cutting-edge immunology treatments and rare disease therapies, positioning itself for long-term growth in a competitive pharmaceutical landscape.

US FDA approves Moderna's next-generation COVID vaccine for adults 65 or older
US FDA approves Moderna's next-generation COVID vaccine for adults 65 or older

Business Recorder

time31-05-2025

  • Business Recorder

US FDA approves Moderna's next-generation COVID vaccine for adults 65 or older

The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, the company said on Saturday, the first endorsement since the regulator tightened requirements. The vaccine has also been approved for people aged 12 to 64 with at least one or more underlying risk factors defined by the Centers for Disease Control and Prevention, Moderna said in a statement. The company said it expects to have the vaccine, called mNEXSPIKE, available for the 2025-2026 respiratory virus season. 'The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,' CEO Stephane Bancel said in the statement. The Department of Health and Human Services, under the leadership of long-time vaccine skeptic Robert F. Kennedy Jr., is tightening regulatory scrutiny on vaccines. The FDA said on May 20 it planned to require drugmakers to test their COVID booster shots against an inert placebo in healthy adults under 65 for approval, effectively limiting them to older adults and those at risk of developing severe illness. The Moderna vaccine can be stored in refrigerators rather than freezers, to offer longer shelf life and make distribution easier, especially in developing countries where supply-chain issues could hamper vaccination drives. The Centers for Disease Control and Prevention, which Kennedy also oversees, said on Thursday that COVID vaccines remain an option for healthy children when parents and doctors agree that it is needed, stopping short of Kennedy's announcement days earlier that the agency would remove the shots from its immunization schedule. The CDC announcement eases investor concern to some extent, analysts say, as it keeps the existing framework for older adults and at-risk people who generally seek out the shots. FDA leaders have said 100 million to 200 million Americans would still be eligible for annual shots. Moderna is betting on its newer messenger RNA vaccines as it grapples with waning demand for its original COVID vaccine Spikevax and lower-than-expected uptake of its respiratory syncytial virus vaccine. The approval for mNEXSPIKE was based on late-stage trial data, which showed the shot was not inferior in efficacy compared to Spikevax in individuals aged 12 years and older. The shot also showed superior efficacy compared to Spikevax in adults 18 years of age and older in the study. Kennedy has kickstarted a major overhaul of health departments, laying off thousands of employees to align with President Donald Trump's goal of dramatically shrinking the federal government. This has further ignited worries about potential disruptions to the regulatory review of treatments and vaccines. The CDC's outside panel of vaccine experts in April discussed recommending the booster shots only for populations at risk of severe COVID-19 for the upcoming immunization campaign. The FDA approved Novavax's COVID vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness. Conditions that constitute additional risk range from illnesses such as diabetes and heart disease to behaviors like physical inactivity and substance abuse, according to the CDC. While Moderna's shots, as well as Pfizer-BioNTech's Comirnaty, are mRNA-based, Novavax's vaccine is protein-based and takes longer to manufacture. Moderna this month withdrew an application seeking approval for its flu-and-COVID combination vaccine candidate to wait for efficacy data from a late-stage trial of its influenza shot.

RFK Jr. halts routine COVID-19 vaccines for pregnant women, children
RFK Jr. halts routine COVID-19 vaccines for pregnant women, children

Express Tribune

time28-05-2025

  • Express Tribune

RFK Jr. halts routine COVID-19 vaccines for pregnant women, children

Vials labelled "VACCINE Coronavirus COVID-19" and a syringe are seen in front of a displayed U.S. flag in this illustration taken December 11, 2021. PHOTO:REUTERS Listen to article The US has stopped recommending routine COVID-19 vaccinations for pregnant women and healthy children, Health Secretary Robert F. Kennedy Jr announced in a social media post on Tuesday, circumventing the CDC's traditional recommendation process. Kennedy, FDA commissioner Marty Makary and National Institutes of Health director Jay Bhattacharya said in a video that the shots have been removed from the Centres for Disease Control and Prevention's recommended immunization schedule. The changes come a week after they unveiled tighter requirements for COVID shots, effectively limiting them to older adults and those at risk of developing severe illness. ‼️🇺🇸 BREAKING: Robert Kennedy Jr announces C0V1D VACC1NE for healthy CHILDREN and healthy PREGNANT WOMEN has been REMOVED from the CDC web page recommended IMMUNIZATION SCHEDULE. 😎 This is a BIG WIN for our children! 🇺🇸 — Diligent Denizen 🇺🇸 (@DiligentDenizen) May 27, 2025 Traditionally, the CDC's Advisory Committee for Immunization Practices would meet and vote on changes to the immunization schedule or recommendations on who should get vaccines before the director of the CDC made a final call. READ: Asia sees fresh spike in Covid-19 cases The committee has not voted on these changes. Kennedy, a long-time vaccine skeptic whose department oversees the CDC, has been remaking the US health system to align with President Donald Trump's goal of dramatically shrinking the federal government. Turned upsidedown "The recommendation is coming down from the secretary, so the process has just been turned upside down," said William Schaffner, professor of infectious diseases at Vanderbilt University Medical Center and a consultant to the ACIP. Schaffner said the CDC's panel was to vote on these issues at a June meeting, where he had expected them to favor more targeted shots instead of a universal vaccine recommendation. "But this seems to be a bit preemptory," he said. Dorit Reiss, professor of law at UC Law San Francisco, said in a Facebook post that going around the advisory committee might hurt the agency in the case of potential litigation. READ MORE: WHO adopts pandemic accord without US as RFK Jr. confirms Washington's withdrawal Studies with hundreds of thousands of people around the world show that COVID-19 vaccination before and during pregnancy is safe, effective, and beneficial to both the pregnant woman and the baby, according to the CDC's website. But Makary said in the video that there was no evidence that healthy children need routine COVID shots. Most countries have stopped recommending it for children, he added. COVID vaccine makers Moderna and Pfizer did not respond to requests for comment. Dr. Cody Meissner, professor of pediatrics at Dartmouth, who co-wrote an editorial with Makary during the COVID pandemic against masks for children, said he agreed with the decision. He said he felt the US had been overemphasizing the importance of the COVID vaccine for young children and pregnant women, and that previous recommendations were based on politics, adding that the severity of the illness generated by the virus seems to have lessened over time in young children.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store